Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2025)

10x Genomics' Total Non-Current Liabilities history spans 8 years, with the latest figure at $238.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 17.25% year-over-year to $238.6 million; the TTM value through Dec 2025 reached $238.6 million, up 17.25%, while the annual FY2025 figure was $238.6 million, 17.25% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $238.6 million at 10x Genomics, up from $235.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $238.6 million in Q4 2025 and bottomed at $181.9 million in Q3 2021.
  • The 5-year median for Total Non-Current Liabilities is $200.8 million (2024), against an average of $203.5 million.
  • The largest annual shift saw Total Non-Current Liabilities dropped 14.75% in 2021 before it grew 18.01% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $193.0 million in 2021, then rose by 14.11% to $220.3 million in 2022, then dropped by 0.2% to $219.8 million in 2023, then dropped by 7.44% to $203.5 million in 2024, then rose by 17.25% to $238.6 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Total Non-Current Liabilities are $238.6 million (Q4 2025), $235.8 million (Q3 2025), and $200.6 million (Q2 2025).